Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Multiple Sclerosis

  Free Subscription


11.03.2024

1 Int J Neurosci
1 J Immunol
1 J Neuroimmunol
5 J Neurol
2 J Neurol Neurosurg Psychiatry
3 Mult Scler
1 Nat Rev Neurol
2 Neurology
1 PLoS One
1 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Int J Neurosci

  1. HUYNH TLT, Feasel CD, Jeng B, Motl RW, et al
    Cross-sectional, comparative study of health-related quality of life across the adult lifespan in multiple sclerosis.
    Int J Neurosci. 2024 Mar 5:1-10. doi: 10.1080/00207454.2024.2327404.
    PubMed         Abstract available


    J Immunol

  2. DAR AA, Ortega Y, Aktas S, Wu K, et al
    CRL4b Inhibition Ameliorates Experimental Autoimmune Encephalomyelitis Progression.
    J Immunol. 2024 Jan 24:ji2300754. doi: 10.4049/jimmunol.2300754.
    PubMed         Abstract available


    J Neuroimmunol

  3. HAHAM N, Zveik O, Rechtman A, Brill L, et al
    Altered immune co-inhibitory receptor expression and correlation of LAG-3 expression to disease severity in NMOSD.
    J Neuroimmunol. 2024;388:578289.
    PubMed         Abstract available


    J Neurol

  4. KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
    The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
    PubMed         Abstract available

  5. HEGEN H, Berek K, Deisenhammer F, Berger T, et al
    Sex impacts treatment decisions in multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
    PubMed         Abstract available

  6. HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
    Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
    PubMed         Abstract available

  7. ZID Y, Robertson NP
    Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
    J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
    PubMed        

  8. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
    PubMed         Abstract available


    J Neurol Neurosurg Psychiatry

  9. FOONG YC, Merlo D, Gresle M, Buzzard K, et al
    Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332883.
    PubMed         Abstract available

  10. JING J, Zhang Z, Su L, Gao C, et al
    Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T MRI.
    J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332566.
    PubMed         Abstract available


    Mult Scler

  11. MONTALBAN X, Piasecka-Stryczynska K, Kuhle J, Benkert P, et al
    Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
    Mult Scler. 2024 Mar 4:13524585241234783. doi: 10.1177/13524585241234783.
    PubMed         Abstract available

  12. APREA MG, Schiavetti I, Portaccio E, Ballerini C, et al
    Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241232266. doi: 10.1177/13524585241232266.
    PubMed         Abstract available

  13. HILLERT J, Bove R, Haddad LB, Hellwig K, et al
    Expert opinion on the use of contraception in people with multiple sclerosis.
    Mult Scler. 2024 Mar 8:13524585241228103. doi: 10.1177/13524585241228103.
    PubMed         Abstract available


    Nat Rev Neurol

  14. FYFE I
    Mitochondrial DNA marks multiple sclerosis.
    Nat Rev Neurol. 2024 Mar 5. doi: 10.1038/s41582-024-00948.
    PubMed        


    Neurology

  15. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
    MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
    Neurology. 2024;102:e209199.
    PubMed         Abstract available

  16. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    PubMed         Abstract available


    PLoS One

  17. JOZEF M, Locatelli I, Brecl Jakob G, Savsek L, et al
    Psychometric evaluation of the 5-item Medication Adherence Report Scale questionnaire in persons with multiple sclerosis.
    PLoS One. 2024;19:e0294116.
    PubMed         Abstract available


    Rev Neurol (Paris)

  18. HAY M, Leguy S, Cahagne V, Lassalle N, et al
    Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
    Rev Neurol (Paris). 2024 Feb 29:S0035-3787(24)00371.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.